Topics

Bayer's Vitravki poised to become first tumour-agnostic therapy in EU following CHMP recommendation

06:51 EDT 30 Jul 2019 | Pharmafile

Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) could be set to become the European Union’s first drug approved in a tumour-agnostic indication after it emerged that it had secured a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).

The committee backed the approval of the therapy for the treatment of both adult and paediatric patients with solid tumours that a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, or whose disease is locally advanced, metastatic or where surgical resection is anticip

read more

Original Article: Bayer's Vitravki poised to become first tumour-agnostic therapy in EU following CHMP recommendation

NEXT ARTICLE

More From BioPortfolio on "Bayer's Vitravki poised to become first tumour-agnostic therapy in EU following CHMP recommendation"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...